Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05160922 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Crizotinib Continuation Clinical Study

StatusActive, Not Recruiting
PhasePhase 4
SponsorPfizer
Started2021-12-27
View on ClinicalTrials.gov ↗
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.

Amendment record

Amended 23 times since 2021-12-06; most recent filed 2026-03-24. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-03-24
Amendment Study Status, Eligibility, Contacts/Locations, IPDSharing v23
2025-08-26
Amendment Study Status, Study Design v22
2025-02-12
Amendment Study Status, Oversight, Contacts/Locations v21
2024-10-09
Amendment Study Identification, Study Status v20
2024-06-24
Amendment Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v19
2023-11-07
Amendment Study Status, Contacts/Locations v18
2023-09-15
Amendment Study Status, Contacts/Locations v17
2023-08-31
Amendment Study Status, Contacts/Locations v16
2023-08-21
Amendment Study Status, Contacts/Locations v15
2023-07-19
Amendment Study Status, Contacts/Locations v14
2023-07-05
Amendment Study Status, Contacts/Locations v13
2023-06-02
Amendment Study Status, Contacts/Locations v12
2023-05-23
Amendment Study Status, Contacts/Locations v11
2023-04-25
Amendment Study Status, Contacts/Locations v10
2023-04-20
Amendment Study Status, Contacts/Locations v9
2023-03-23
Amendment Study Status, Contacts/Locations v8
2023-02-22
Amendment Study Status, Contacts/Locations v7
2023-01-18
Amendment Study Status, Contacts/Locations v6
2023-01-12
Amendment Study Status, Contacts/Locations v5
2022-08-30
Amendment Study Status, Contacts/Locations v4
2022-08-15
Amendment Study Status, Contacts/Locations v3
2022-06-27
Amendment Study Status, Contacts/Locations v2
2022-01-14
Amendment Not Yet Recruiting→Recruiting Study Identification, Study Status, Oversight, Contacts/Locations v1
2021-12-06
Original filing
Trial Details
NCT Number NCT05160922
Lead Sponsor Pfizer
Conditions NSCLC, ALCL, IMT
Enrollment 27 participants
Start Date 2021-12-27
Primary Completion 2028-03-21 (estimated)
Study Completion 2028-03-21 (estimated)
Updated on ClinicalTrials.gov 2026-03-30